Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among... NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Mehr anzeigen
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement PR Newswire CAMBRIDGE, Mass., Jan. 6, 2025 NeuroSense in Compliance with all Nasdaq Listing RequirementsCAMBRIDGE, Mass...
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS PR Newswire CAMBRIDGE, Mass., Dec. 23, 2024 Binding Term Sheet with a leading global pharmaceutical company includes a...
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024 CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics...
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass., Dec. 11, 2024 The Type C meeting with the FDA, combined with the recent 18-month Phase...
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS PR Newswire CAMBRIDGE, Mass., Dec. 4, 2024 In participants who...
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR Newswire CAMBRIDGE, Mass., Dec. 2, 2024 CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense...
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE, Mass., Nov. 21, 2024 CAMBRIDGE, Mass., Nov. 21, 2024 /PRNewswire/ -- NeuroSense...
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE, Mass., Oct. 28, 2024 Meeting discussion to focus on finalizing Phase 3 study design...
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct. 24, 2024 Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE...
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates PR Newswire CAMBRIDGE, Mass., Oct. 15, 2024 Dossier submission planned...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.06 | 5.60747663551 | 1.07 | 1.14 | 1.0101 | 167314 | 1.11065219 | CS |
| 4 | -0.11 | -8.87096774194 | 1.24 | 1.33 | 1 | 168599 | 1.1723897 | CS |
| 12 | -0.182 | -13.8719512195 | 1.312 | 1.42 | 0.8 | 293040 | 1.14656852 | CS |
| 26 | 0.38 | 50.6666666667 | 0.75 | 1.455 | 0.5985 | 279708 | 1.02784039 | CS |
| 52 | 0.218 | 23.9035087719 | 0.912 | 2.33 | 0.512 | 277290 | 1.19626646 | CS |
| 156 | -1.18 | -51.0822510823 | 2.31 | 8.18 | 0.4 | 983441 | 3.39021564 | CS |
| 260 | -3.42 | -75.1648351648 | 4.55 | 8.18 | 0.4 | 961361 | 3.38476466 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
